Alopecia Areata Is Not Cosmetic Hair Loss: What Do the Upadacitinib Trials Show?
Upadacitinib results in severe alopecia areata from two phase 3 trials, the safety limits, and the key differences from cosmetic hair loss.
Hair loss is not a single disease. Androgenetic alopecia, telogen effluvium, hair-shaft breakage and alopecia areata may look alike, but their causes and treatments differ. Alopecia areata is an autoimmune disease in which the immune system targets the hair follicle; it can progress from patchy loss to loss affecting the whole scalp and sometimes body hair.
This distinction is critical when interpreting two large phase 3 trials of upadacitinib. The findings are not evidence for a cosmetic hair serum, a vitamin supplement or routine male-pattern hair loss treatment. The trials evaluated a systemic JAK inhibitor in adults and adolescents with severe alopecia areata.
How were the two phase 3 trials designed?
UP-AA1 and UP-AA2, published online in JAMA Dermatology on 12 August 2026 (opens in a new tab), were two replicate, parallel, randomised, double-blind, placebo-controlled phase 3 trials. The programme ran from October 2023 to July 2025 and included 1,399 participants with severe alopecia areata, aged 12 to under 64, with a baseline SALT score of at least 50: 1,281 adults and 118 adolescents.
Participants were randomised 2:2:1 to upadacitinib 15 mg, upadacitinib 30 mg or placebo once daily. The first 24 weeks were placebo-controlled. The primary endpoint was a SALT score of 20 or lower at week 24. This threshold means hair is present on at least about 80% of the scalp; it is not the same as “complete recovery”.
How large were the results?
In UP-AA1, the proportion reaching SALT ≤20 at week 24 (opens in a new tab) was 45.2% with 15 mg, 55.0% with 30 mg and 1.5% with placebo. In UP-AA2 the corresponding rates were reported as 44.6%, 54.3% and 3.4%. Both doses were statistically superior to placebo in both trials.
These results show that roughly one in two participants with severe disease reached the primary threshold at 24 weeks. They also show that the other half did not. Headlines such as “the drug cured baldness” or “it definitely regrows hair” are therefore not scientifically accurate.
Improvements were also reported in eyebrow and eyelash outcomes and in quality-of-life measures. But the core clinical message of this article is that the trials measured a defined treatment response in a severe autoimmune disease, not a cosmetic increase in density.
How should the safety data be read?
During the 24-week controlled period, the investigators reported no new safety signal and a profile consistent with upadacitinib’s other approved indications. That does not mean “risk-free”. Upadacitinib is a systemic JAK inhibitor; because of class and product warnings (opens in a new tab) such as serious infections, malignancy, major adverse cardiovascular events and thrombosis, it requires patient selection, screening and monitoring.
In UP-AA2, two participants receiving 30 mg discontinued because of serious adverse events; the report lists streptococcal pneumonia and vertebral artery stenosis. Individual events do not prove causation, but they show why a safety assessment cannot be reduced to the sentence “no new signal”.
The industry sponsorship of the trials and the authors’ conflicts of interest should also be considered. Phase 3 randomisation and results replicated across two trials strengthen the evidence; a sponsored design does not remove the need for independent long-term and real-world data.
Why does regulatory status vary by country?
In the European Union, upadacitinib is approved for severe alopecia areata in adults and adolescents aged 12 and older: the manufacturer announced European Commission approval in July 2026 (opens in a new tab), and the indication appears on the European Medicines Agency’s product page (opens in a new tab). In the United States, the manufacturer announced in April 2026 that it had submitted a supplemental application to the FDA (opens in a new tab). As of 9 October 2026, the date this article was published, the current FDA label (opens in a new tab) does not include an alopecia areata indication, so it should not be read as approved for this use in the US.
A drug being on the market for other diseases does not mean it is approved for alopecia areata in every country. Off-label use, reimbursement and prescribing conditions may vary by country.
Who should not apply these results to themselves?
The trial results cannot be applied directly to androgenetic alopecia, postpartum hair loss, iron-deficiency-related loss, stress-related telogen effluvium or cosmetic breakage. Rates obtained in a severe alopecia areata population with SALT ≥50 do not guarantee the same benefit–risk balance in patients with a few small patches.
The type of hair loss is distinguished through examination, history and, when needed, dermoscopy or laboratory tests. A systemic JAK inhibitor is not a cosmetic option to be started on the basis of online content.
The LCY verdict
UP-AA1 and UP-AA2 provide strong, replicated phase 3 evidence for the 24-week efficacy of upadacitinib in severe alopecia areata. We rate the level of evidence as B: the results of two large randomised trials replicate convincingly, but long-term safety, durability after stopping treatment, rare adverse events, independent real-world data and country-specific regulatory status still matter.
The most accurate headline is not “a new solution for hair loss”. The accurate conclusion is this: severe alopecia areata is an autoimmune disease distinct from cosmetic hair loss, and upadacitinib has shown a meaningful scalp response in this selected patient group.
